MNK1/2 inhibition limits oncogenicity and metastasis of KIT-mutant melanoma

نویسندگان
چکیده

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Imatinib targeting of KIT-mutant oncoprotein in melanoma.

PURPOSE Melanoma subtypes based on anatomic location and UV light exposure can be further classified based on genetic alterations recently identified. Mutations and gene amplification in KIT have been described in a significant percentage of mucosal and acral melanomas. We recently reported a patient with metastatic mucosal melanoma harboring a known KIT mutation treated with imatinib mesylate ...

متن کامل

Comparison of c-Kit expression between primary and metastatic melanoma of skin and mucosa

  Background: Melanoma causes the greatest morbidity and mortality of all skin cancers. Mucosal melanoma is a rare but highly aggressive neoplasm. According to previous studies the prevalence of KIT mutations in acrallentiginous and mucosal melanomas is relatively low (less than 15–20%), but it can have profound therapeutic implications for localized high risk or metastatic diseases. Our goal w...

متن کامل

Inhibition of melanoma growth and metastasis by ATF2-derived peptides.

The resistance of melanoma to apoptosis, as well as its growth and metastasis capabilities, can be overcome by expression of a peptide derived from amino acid (aa) 51 to 100 of ATF2. Here we show that expression of ATF2((51-100)) in human melanoma cells reduced their growth in nude mice, which was additionally inhibited upon treatment with protein kinase inhibitors UCN-01 or SB203580. Injection...

متن کامل

Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition.

PURPOSE Although durable responses can be achieved with tyrosine kinase inhibitors such as imatinib in melanomas harboring KIT mutations, the efficacy of alternative inhibitors after progression to imatinib and the activity of these agents on brain metastases are unknown. EXPERIMENTAL DESIGN We conducted a phase II study of nilotinib 400 mg twice a day in two cohorts of patients with melanoma...

متن کامل

Respiratory mutant and liquid holding recovery inhibition in yeast cells

Background: Cell ability to recover from radiation damage is of great relevance in cancer treatment. It is often believed that the inhibition of cell ability to the liquid holding recovery (LHR) may be an indicator of the overall suppression of cell ability to recover from potentially lethal radiation damage. However, the literature contains no experimental evidence whether the LHR inhibition m...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

ژورنال

عنوان ژورنال: Journal of Clinical Investigation

سال: 2017

ISSN: 0021-9738,1558-8238

DOI: 10.1172/jci91258